Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Wolfgang Miesbach: First Lp(a)‑Specific Therapy in Secondary Prevention?
Wolfgang Miesbach, Klaus Parhofer/LinkedIn; Elisabeth Steinhagen-Thiessen/Charite
May 19, 2026, 14:53

Wolfgang Miesbach: First Lp(a)‑Specific Therapy in Secondary Prevention?

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Klaus G Parhofer et al, published in European Heart Journal, adding:

”First Lp(a)‑Specific Therapy in Secondary Prevention?

Pelacarsen Slashes Apheresis in Established CVD.

Elevated lipoprotein(a) [Lp(a)] is a frequent, genetically driven and largely lifestyle‑independent risk factor, present in approximately 20% of the general population and up to 25% of patients with ASCVD – yet we still have no approved Lp(a)‑lowering drug.

In the German Phase 3 Lp(a)FRONTIERS APHERESIS trial (51 patients with established CVD, isolated Lp(a) >60 mg/dL and a median of 44 LA sessions/year), pelacarsen 80 mg SC every 4 weeks almost abolished the need for weekly Lp(a) apheresis:

  • normalized LA rate from 0.93 to 0.16 (≈99% reduction in odds of requiring LA),
  • 69% complete LA avoidance from week 12–52 vs 0% on placebo,
  • and ~72–77% sustained Lp(a) lowering, with mainly mild injection‑site reactions.

Huge congratulations to Dr Klaus Parhofer, Elisabeth Steinhagen-Thiessen and all co‑authors on these impressive data.

Pelacarsen may represent a major step toward a targeted, scalable therapy for genetically elevated Lp(a) in secondary prevention.”

Title: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial

Authors: Klaus G. Parhofer, Ulrich Julius, Anna Laura Herzog, Thilo Krüger, Julia Weinmann-Menke, Gunnar H. Heine, Hui Cao, Jessica Schorr, Philippe Ferber, Jing Wang, Enrico Cristante, Björn Müller-Edenborn, Anja Vogt, Volker Schettler, Elisabeth Steinhagen-Thiessen

Wolfgang Miesbach: First Lp(a)‑Specific Therapy in Secondary Prevention?

Stay updated on all scientific advances with Hemostasis Today.

Anja Vogt Anna Laura Herzog apheresis ASCVD Björn Müller-Edenborn CVD Elisabeth Steinhagen-Thiessen Enrico Cristante European Heart Journal FRONTIERS APHERESIS Gunnar H. Heine Health Hematology Hemostasis Hemostasis News Hemostasis Today Hui Cao Jessica Schorr Jing Wang Julia Weinmann-Menke Klaus G. Parhofer LA Lp(a) Medicine Pelacarsen Philippe Ferber Thilo Krüger thrombosis Ulrich Julius Volker Schettler Wolfgang Miesbach
NewsFeed